Sign in
SCHEDULE 13G/A

Statement of Beneficial Ownership

SAB Biotherapeutics, Inc. Filed Acc 0001213900-26-120155

Stakes reported in this filing

Reporting person Shares Of the class
Vivo Opportunity Fund Holdings, L.P. 22,287,501 9.99%
Vivo Opportunity, LLC 22,287,501 9.99%
Vivo Opportunity Cayman Fund, L.P. 2,251,010 9.99%
Vivo Opportunity Cayman, LLC 2,251,010 9.99%

Members of a group can each report the same shares, so these rows overlap and don't add up.

Loading xslSCHEDULE_13G_X02/primary_doc.xml…